A recent study published in the journal Allergy by Trinity College Dublin researchers focused on chronic spontaneous urticaria (CSU), a common skin condition characterized by recurrent hives. The study found a link between rare immune cell types and treatment response in CSU patients who responded well to omalizumab. The research, led by Professor Niall Conlon, highlighted the impact of CSU on quality of life and the challenges in diagnosing and managing the condition. Understanding the role of these rare immune cells could potentially help predict treatment responses in CSU and other allergic diseases.
Source link
Study reveals how extremely rare immune cells predict how well treatments work for recurrent hives
